Salarius Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Houstontexasfounded In 2014The Company Focuses On Developing Therapies For Cancers With Limited Treatment Optionsparticularly Pediatric Cancerssarcomasand Hematologic Malignanciessalarius Employs A Small Team And Operates With A Clinical Stage Revenue Model The Company Specializes In Correcting Dysregulated Gene Expression Through Two Main Therapeutic Approachestargeted Protein Inhibitiontpiand Targeted Protein Degradationtpd Its Pipeline Includes Seclidemstatsp 2577 An Oral Small Molecule Lsd1 Inhibitor Targeting Various Cancersand Sp 3164An Oral Cereblon Binding Molecular Glue Degrader Aimed At Treating Non Hodgkinae S Lymphomaadditionallysalarius Is Developing A Second Generation Lsd1 Inhibitor For Hematologic And Solid Tumorsthe Company Recently Expanded Its Pipeline By Acquiring Decoy Therapeutics Incin January 2025
